| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 38 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 38 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 38 |
| 3 | ETOPOSIDE | 31 |
| 4 | DEXAMETHASONE | 26 |
| 5 | DEXAMETHASONE 1.5 MG | 26 |
| 6 | DOXORUBICIN | 23 |
| 7 | RITUXIMAB | 23 |
| 8 | CYTARABINE | 19 |
| 9 | IFOSFAMIDE | 19 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | VINORELBINE | 16 | 0.0023 |
| 1 | GRANULOCYTE COLONY STIMULATING FACTOR | 5 | 0.0023 |
| 2 | PONATINIB HYDROCHLORIDE | 9 | 0.0017 |
| 3 | BRENTUXIMAB VEDOTIN | 17 | 0.0016 |
| 4 | PENTAMIDINE ISETHIONATE | 2 | 0.0016 |
| 5 | PLERIXAFOR | 2 | 0.0013 |
| 6 | GENTAMICIN SULFATE | 15 | 0.0009 |
| 7 | IFOSFAMIDE FOR INJECTION | 19 | 0.0009 |
| 8 | ACYCLOVIR SODIUM | 1 | 0.0008 |
| 9 | ETOPOSIDE PHOSPHATE | 1 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 40 |
| 1 | Corticosteroid [EPC] | 40 |
| 2 | Topoisomerase Inhibitor [EPC] | 31 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 23 |
| 4 | Platinum-based Drug [EPC] | 20 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 19 |
| 6 | CD30-directed Immunoconjugate [EPC] | 17 |
| 7 | Leukocyte Growth Factor [EPC] | 15 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 13 |
| 9 | Phosphodiesterase 5 Inhibitor [EPC] | 11 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD30-directed Immunoconjugate [EPC] | 17 | 0.0016 |
| 1 | Hematopoietic Stem Cell Mobilizer [EPC] | 2 | 0.0013 |
| 2 | CD38-directed Cytolytic Antibody [EPC] | 5 | 0.0009 |
| 3 | Topoisomerase Inhibitor [EPC] | 31 | 0.0004 |
| 4 | Lipid-based Polyene Antifungal [EPC] | 4 | 0.0003 |
| 5 | Alkylating Drug [EPC] | 40 | 0.0002 |
| 6 | Penem Antibacterial [EPC] | 4 | 0.0001 |
| 7 | Leukocyte Growth Factor [EPC] | 15 | 0.0001 |
| 8 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 10 | 0.0001 |
| 9 | Polyene Antifungal [EPC] | 4 | 0.0001 |